Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth

Cancer Gene Ther. 2010 May;17(5):325-33. doi: 10.1038/cgt.2009.75. Epub 2009 Oct 23.

Abstract

The aim of this study was to assess the biological consequences of cyclin D1 silencing in pancreatic cancer cells. A replication-defective lentivirus based small hairpin RNA (shRNA) system targeting cyclin D1 caused a marked reduction in cyclin D1 protein levels in ASPC-1 and BxPC3 pancreatic cancer cell lines in conjunction with decreased cell growth and invasiveness in vitro. Moreover, a single intratumoral injection of the recombinant lentivirus targeting cyclin D1 attenuated the growth of pre-existing tumors arising from two distinct cell lines. This attenuated growth correlated with decreased proliferation and angiogenesis, as well as attenuated vascular endothelial growth factor expression. It is concluded that lentivirus-delivered shRNA targeting cyclin D1 suppresses the growth, invasiveness, tumorigenicity and pro-angiogenic potential of human pancreatic cancer cells, thereby raising the possibility that intratumoral injections of viruses targeting cyclin D1 could provide a new therapeutic approach in pancreatic ductal adenocarcinoma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation
  • Cyclin D1 / genetics
  • Cyclin D1 / metabolism*
  • Genetic Therapy*
  • Genetic Vectors / genetics
  • Humans
  • Immunoblotting
  • Immunohistochemistry
  • Lentivirus / genetics
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / therapy*

Substances

  • Cyclin D1